Implementing an electronic end-of-life chemotherapy utilization measure

March 19, 2020

Kraut J, Mooney K, Sweetenham JW, Page RD, Adelson K, Agarwala V, Fessele KL, Hamrick HJ, Kaganman I, Martineau J, Abernethy AP, and Meropol NJ. Journal of Oncology Practice. .

http://ascopubs.org/doi/abs/10.1200/JOP.18.00408

Authors:
Kraut J, Mooney K, Sweetenham JW, Page RD, Adelson K, Agarwala V, Fessele KL, Hamrick HJ, Kaganman I, Martineau J, Abernethy AP, and Meropol NJ

Sources:
Journal of Oncology Practice

Read the research

Posted in

Treatment and Testing patterns

More publications

May 2026

Real-world treatment patterns and outcomes among patients with high-risk and very high-risk non-metastatic prostate cancer

May 2026

Real-world second-line treatment patterns and outcomes by platinum sensitivity in extensive-stage small cell lung cancer in the post-immunotherapy era

April 2026

Implementing an electronic end-of-life chemotherapy utilization measure

Share

Posted in

More publications

Real-world treatment patterns and outcomes among patients with high-risk and very high-risk non-metastatic prostate cancer

Real-world second-line treatment patterns and outcomes by platinum sensitivity in extensive-stage small cell lung cancer in the post-immunotherapy era

Real-world clinical outcomes in patients with CLL previously treated with covalent BTKi and BCL2i regimens